Extracellular vesicles (EVs) — including exosomes, microvesicles, and apoptotic bodies — are lipid bilayer particles released by virtually all cell types. They carry cargo including proteins, lipids, RNAs, and mitochondria that can be harnessed for neuroprotective therapy in neurodegenerative diseases [1][7].
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8/10 | EVs as therapeutic vehicles is established but cell-type specific targeting and engineered cargo is novel |
| Mechanistic Rationale | 9/10 | Strong preclinical data across AD/PD/ALS models |
| Root-Cause Coverage | 7/10 | Addresses protein aggregation, mitochondrial dysfunction, inflammation |
| Delivery Feasibility | 8/10 | EVs naturally cross BBB; scalable manufacturing developing |
| Safety Plausibility | 8/10 | Cell-derived EVs show favorable safety in clinical trials |
| Combinability | 9/10 | Can combine multiple cargo types; compatible with other therapies |
| Biomarker Availability | 6/10 | EV cargo quantification possible but not standardized |
| De-risking Path | 7/10 | Multiple Phase I trials ongoing; clear regulatory path |
| Multi-disease Potential | 9/10 | Strong rationale across AD, PD, ALS, FTD, stroke |
| Patient Impact | 8/10 | Potential for disease modification vs. symptom relief |
Total: 79/100
| Disease | Coverage | Evidence Strength |
|---|---|---|
| Alzheimer's Disease | AD(9) | Strong |
| Parkinson's Disease | PD(8) | Strong |
| ALS | ALS(7) | Moderate |
| FTD | FTD(7) | Moderate |
| Aging | Aging(8) | Strong |